SEC Sent Alexion Pharmaceuticals a Subpoena in May
The SEC’s investigation focuses on potential Foreign Corrupt Practices Act violations in connection with “grant-making activities,” Alexion wrote in the 10-Q filing.
To read more
Subscribe to Global Investigations Review
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the Global Investigations Review experts.
Already have access? Login below
Copyright © Law Business ResearchCompany Number: 03281866 VAT: GB 160 7529 10